Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma

Author:

Liapis Vasilios1,Zysk Aneta1,DeNichilo Mark2,Zinonos Irene1,Hay Shelley1,Panagopoulos Vasilios1,Shoubridge Alexandra1,Difelice Christopher1,Ponomarev Vladimir3,Ingman Wendy45,Atkins Gerald J.6,Findlay David M.6,Zannettino Andrew C. W.7,Evdokiou Andreas1ORCID

Affiliation:

1. Discipline of Surgery; Breast Cancer Research Unit; Basil Hetzel Institute and Centre for Personalised Cancer Medicine; University of Adelaide; Woodville South Australia Australia

2. Vascular Biology and Cell Trafficking Laboratory; Centre for Cancer Biology; University of South Australia; Adelaide South Australia Australia

3. Department of Radiology; Memorial Sloan-Kettering Cancer Center; New York New York

4. Discipline of Surgery; School of Medicine at The Queen Elizabeth Hospital; University of Adelaide; Woodville Australia

5. Robinson Research Institute; University of Adelaide; Adelaide Australia

6. Discipline of Orthopaedics and Trauma; University of Adelaide; Adelaide South Australia Australia

7. School of Medical Sciences; Myeloma Research Laboratory Cancer Theme; South Australian Health and Medical Research Institute (SAHMRI); Faculty of Health Science; University of Adelaide; Adelaide Australia

Funder

National Health and Medical Research Council

Hospital Research Foundation

National Breast Cancer Foundation

Breast Cancer Research Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference43 articles.

1. Bone and Soft Tissue Tumors

2. Osteosarcoma development and stem cell differentiation;Tang;Clin. Orthop. Relat. Res.,2008

3. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study;Link;Clin. Orthop. Relat. Res.,1991

4. Chemotherapy for osteosarcoma and Ewing's sarcoma;Saeter;Acta Orthop. Scand.,1997

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3